Novocell CEO to Head Juvenile Diabetes Research Foundation (JDRF)

/Novocell CEO to Head Juvenile Diabetes Research Foundation (JDRF)

San Diego, CA (November 25, 2008) – Novocell, Inc., a stem cell engineering company, today announced that President and Chief Executive Officer Alan J. Lewis, Ph.D., will leave the company effective January 1, 2009 to become the President and CEO of the Juvenile Diabetes Research Foundation.

“Alan has contributed significantly to building Novocell into the leading innovator in the development of stem cell technologies for the treatment of diabetes,” said Fred Middleton, Chairman of the Novocell Board of Directors and Managing Director, Sanderling Ventures. “It seems a wise and logical choice for JDRF to tap Alan for this job as a way for them to access the frontiers of the most promising research initiatives being developed for diabetes therapy. The mission of Novocell’s researchers continues to be to develop stem cell technology for clinical therapy. We wish Alan well in his new position at the JDRF, and we thank him for his contributions to Novocell.”

“It has been rewarding to be a part of a company that has pioneered the development of stem cell therapy, including the development of technologies that hold promise for the treatment of diabetes,” said Lewis. “I look forward to joining JDRF to continue the same mission as Novocell’s: to develop a cure for Type 1 diabetes – a mission closely tied to our work at Novocell.”

Dr. Alan Lewis joined Novocell in February 2006 as CEO. In the past three years, Novocell has published three of the leading publications outlining the biological path for creating functional islets from stem cells. Based on these advances in stem cell technology, Novocell has begun a development program to prepare its stem cell products for human clinical therapy.

About Novocell

Novocell, Inc. is a stem cell engineering company with research operations in San Diego, California and Athens, Georgia, dedicated to creating, delivering and commercializing cell and drug therapies for diabetes and other chronic diseases. Novocell has three primary technologies: stem cell engineering, cell encapsulation and drug discovery. The Company was founded in 1999 and merged with CyThera, Inc. and BresaGen, Inc. in 2004. For more information, please visit